Get the Stockscreener App
294.44
6.17%
17.11
Pre-market:
297.00
2.56
+0.87%
Charles River Laboratories International Inc stock is traded at $294.44, with a volume of 1.57M.
It is up +6.17% in the last 24 hours and down -1.39% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$277.33
Open:
$277
24h Volume:
1.57M
Relative Volume:
1.67
Market Cap:
$14.06B
Revenue:
$4.03B
Net Income/Loss:
$-182.84M
P/E Ratio:
-78.30
EPS:
-3.7603
Net Cash Flow:
$391.29M
1W Performance:
+4.53%
1M Performance:
-1.39%
6M Performance:
+84.96%
1Y Performance:
+97.02%
1-Day Range:
$276.95
$298.40
1-Week Range:
$275.88
$298.40
52-Week Range:
$144.26
$303.31
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
294.44 | 14.06B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-29-26 | Upgrade | CLSA | Hold → Outperform |
| Apr-14-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating - marketscreener.com
TD Cowen raises Charles River Labs stock price target on growth outlook - Investing.com Canada
Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating - marketscreener.com
Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch - finance.yahoo.com
Charles River Labs stock rises 5.2 percent ahead of the open - AD HOC NEWS
Why Charles River Laboratories (CRL) Stock Is Up Today - finance.yahoo.com
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
Charles River Laboratories (CRL) Reaffirms 2026 Guidance and Unv - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $325 FROM $300 - Bitget
CRL: 2030 targets: 5%-7% sales CAGR, ~24% margins, $300M savings, and digital-driven growth - TradingView
CRL: 2030 targets: 5%-7% sales CAGR, 24% margins, and $300M in savings via AI-driven modernization - TradingView
Charles River Laboratories International Jumps 5.1% in Broad Rally - AlphaStreet
Charles River Laboratories International Inc Stock (CRL) Moved Up by 7.23% on Sep 24: Facts Behind the Movement - TradingKey
Charles River Laboratories rises after reaffirming 2026 outlook and unveiling 2030 targets - quiverquant.com
Charles River stock rises on promising 2026 outlook (CRL:NYSE) - Seeking Alpha
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - Benzinga
Charles River Laboratories International, Inc. (CRL) Analyst/Investor DaySlideshow (NYSE:CRL) 2026-09-24 - Seeking Alpha
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day - BioSpace
Charles River Laboratories International (CRL) As Faster Cell Banking Fuels A Modest Undervalued View - simplywall.st
Charles River Laboratories International, Inc. Investor Day 2026 Transcript - GuruFocus
Over $300M in savings is expected from 2027 to 2030 as Charles River (CRL) sets a revenue growth target. - Stock Titan
Charles River Labs reiterates FY26 outlook, targets 5-7% growth by 2030 - scanx.trade
Charles River Laboratories stock falls 2.73 percent after Q2 results - AD HOC NEWS
Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections - marketscreener.com
CRL: 2030 targets: 5–7% organic revenue CAGR, ~24% margin, and $300M+ in cost savings - TradingView
CRL: Modernization and digitalization drive growth, with 5–7% organic revenue CAGR targeted by 2030 - TradingView
Over $300 million in savings is expected as Charles River automates and simplifies work, 2027–30. - Stock Titan
Charles River Laboratories stock trades below its yearly high - AD HOC NEWS
Charles River Labs stock falls 1.4 percent ahead of the open - AD HOC NEWS
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Labs stock rises 2.19 percent ahead of the open - AD HOC NEWS
Halper Sadeh investigates Charles River Labs over fiduciary breaches - scanx.trade
Charles River Labs Q3 Results: Adj EPS Expected At $2.90$3.00 - scanx.trade
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Charles River Laboratories stock holds near its yearly high - AD HOC NEWS
Charles River Laboratories stock holds near its yearly high on mixed results - AD HOC NEWS
Charles River Labs stock heads into the open after a 1.28 percent drop - AD HOC NEWS
Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter - finance.yahoo.com
Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL) - finance.yahoo.com
Charles River Labs stock trades near record levels on solid earnings outlook - AD HOC NEWS
Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
Charles River Labs stock heads into the open after a flat September 18 close - AD HOC NEWS
Charles River Labs stock gains after rapid cell banking launch - AD HOC NEWS
Charles River Laboratories stock gains on rapid cell banking launch - ad-hoc-news.de
Will Rapid Cell Banking Change Charles River Stock Narrative - simplywall.st
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Can Charles River Laboratories International (CRL) Justify Its Valuation On Its Rapid Cell Banking Launch? - finance.yahoo.com
Charles River Labs stock gains after rapid cell banking launch and analyst target hikes - AD HOC NEWS
What Is Charles River Laboratories International (CRL) Signaling With Its Faster Cell Banking Platform? - finance.yahoo.com
Charles River Laboratories International (CRL) Stock Fair Value Rises After Analysts Lift Targets - finance.yahoo.com
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):